1.

Use of cardiac telerehabilitation during COVID-19 pandemic in Belgium

2.

Use of cardiac telerehabilitation during COVID-19 pandemic in Belgium

3.

Use of cardiac telerehabilitation during COVID-19 pandemic in Belgium

4.

Use of cardiac telerehabilitation during COVID-19 pandemic in Belgium

1.

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care

2.

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care

3.

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care

4.

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care

5.

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care

6.

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care

7.

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care

8.

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care

9.

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care

1.

Baseline demographics of a contemporary Belgian atrial fibrillation cohort included in a large randomised clinical trial on targeted education and integrated care (AF-EduCare/AF-Ed...

2.

Baseline demographics of a contemporary Belgian atrial fibrillation cohort included in a large randomised clinical trial on targeted education and integrated care (AF-EduCare/AF-Ed...

3.

Baseline demographics of a contemporary Belgian atrial fibrillation cohort included in a large randomised clinical trial on targeted education and integrated care (AF-EduCare/AF-Ed...

4.

Baseline demographics of a contemporary Belgian atrial fibrillation cohort included in a large randomised clinical trial on targeted education and integrated care (AF-EduCare/AF-Ed...

5.

Baseline demographics of a contemporary Belgian atrial fibrillation cohort included in a large randomised clinical trial on targeted education and integrated care (AF-EduCare/AF-Ed...

6.

Baseline demographics of a contemporary Belgian atrial fibrillation cohort included in a large randomised clinical trial on targeted education and integrated care (AF-EduCare/AF-Ed...

7.

Baseline demographics of a contemporary Belgian atrial fibrillation cohort included in a large randomised clinical trial on targeted education and integrated care (AF-EduCare/AF-Ed...

8.

Baseline demographics of a contemporary Belgian atrial fibrillation cohort included in a large randomised clinical trial on targeted education and integrated care (AF-EduCare/AF-Ed...

9.

Baseline demographics of a contemporary Belgian atrial fibrillation cohort included in a large randomised clinical trial on targeted education and integrated care (AF-EduCare/AF-Ed...

1.

Adherence to oral anticoagulation measured by electronic monitoring in a Belgian atrial fibrillation population

2.

Adherence to oral anticoagulation measured by electronic monitoring in a Belgian atrial fibrillation population

3.

Adherence to oral anticoagulation measured by electronic monitoring in a Belgian atrial fibrillation population

4.

Adherence to oral anticoagulation measured by electronic monitoring in a Belgian atrial fibrillation population

5.

Adherence to oral anticoagulation measured by electronic monitoring in a Belgian atrial fibrillation population

6.

Adherence to oral anticoagulation measured by electronic monitoring in a Belgian atrial fibrillation population

7.

Adherence to oral anticoagulation measured by electronic monitoring in a Belgian atrial fibrillation population

8.

Adherence to oral anticoagulation measured by electronic monitoring in a Belgian atrial fibrillation population

9.

Adherence to oral anticoagulation measured by electronic monitoring in a Belgian atrial fibrillation population

1.

Development and internal validation of the Digital Health Readiness Questionnaire:Prospective Single-Center Survey Study

2.

Development and internal validation of the Digital Health Readiness Questionnaire:Prospective Single-Center Survey Study

3.

Development and internal validation of the Digital Health Readiness Questionnaire:Prospective Single-Center Survey Study

4.

Development and internal validation of the Digital Health Readiness Questionnaire:Prospective Single-Center Survey Study

5.

Development and internal validation of the Digital Health Readiness Questionnaire:Prospective Single-Center Survey Study

6.

Development and internal validation of the Digital Health Readiness Questionnaire:Prospective Single-Center Survey Study

7.

Development and internal validation of the Digital Health Readiness Questionnaire:Prospective Single-Center Survey Study

8.

Development and internal validation of the Digital Health Readiness Questionnaire:Prospective Single-Center Survey Study

1.

The role of cardiac rehabilitation in vocational reintegration Belgian working group of cardiovascular prevention and rehabilitation position paper

2.

The role of cardiac rehabilitation in vocational reintegration Belgian working group of cardiovascular prevention and rehabilitation position paper

3.

The role of cardiac rehabilitation in vocational reintegration Belgian working group of cardiovascular prevention and rehabilitation position paper

4.

The role of cardiac rehabilitation in vocational reintegration Belgian working group of cardiovascular prevention and rehabilitation position paper

1.

Gender differences in risk factor management and pharmacological treatment among CHD patients: Belgian results of the EUROASPIRE IV and EUROASPIRE V surveys ...

1.

Gender differences in risk factor management and pharmacological treatment among CHD patients: Belgian results of the EUROASPIRE IV and EUROASPIRE V surveys.

2.

Gender differences in risk factor management and pharmacological treatment among CHD patients: Belgian results of the EUROASPIRE IV and EUROASPIRE V surveys.

3.

Gender differences in risk factor management and pharmacological treatment among CHD patients: Belgian results of the EUROASPIRE IV and EUROASPIRE V surveys.

4.

Gender differences in risk factor management and pharmacological treatment among CHD patients: Belgian results of the EUROASPIRE IV and EUROASPIRE V surveys.

5.

Gender differences in risk factor management and pharmacological treatment among CHD patients: Belgian results of the EUROASPIRE IV and EUROASPIRE V surveys.

6.

Gender differences in risk factor management and pharmacological treatment among CHD patients: Belgian results of the EUROASPIRE IV and EUROASPIRE V surveys.

7.

Gender differences in risk factor management and pharmacological treatment among CHD patients: Belgian results of the EUROASPIRE IV and EUROASPIRE V surveys.

8.

Gender differences in risk factor management and pharmacological treatment among CHD patients: Belgian results of the EUROASPIRE IV and EUROASPIRE V surveys.

9.

Gender differences in risk factor management and pharmacological treatment among CHD patients: Belgian results of the EUROASPIRE IV and EUROASPIRE V surveys.